List of investigational anxiolytics

Last updated

This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources.

This is a list of investigational anxiolytics , or anxiolytics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

Contents

This list was last comprehensively updated in June 2017. It is likely to become outdated with time.

Generalized anxiety disorder

Panic disorder

Post-traumatic stress disorder

Social anxiety disorder

Others/unspecified

See also

Related Research Articles

<span class="mw-page-title-main">Noradrenergic and specific serotonergic antidepressant</span> Class of antidepressants

Noradrenergic and specific serotonergic antidepressants (NaSSAs) are a class of psychiatric drugs used primarily as antidepressants. They act by antagonizing the α2-adrenergic receptor and certain serotonin receptors such as 5-HT2A and 5-HT2C, but also 5-HT3, 5-HT6, and/or 5-HT7 in some cases. By blocking α2-adrenergic autoreceptors and heteroreceptors, NaSSAs enhance adrenergic and serotonergic neurotransmission in the brain involved in mood regulation, notably 5-HT1A-mediated transmission. In addition, due to their blockade of certain serotonin receptors, serotonergic neurotransmission is not facilitated in unwanted areas, which prevents the incidence of many side effects often associated with selective serotonin reuptake inhibitor (SSRI) antidepressants; hence, in part, the "specific serotonergic" label of NaSSAs.

<span class="mw-page-title-main">Lisuride</span> Chemical compound

Lisuride, sold under the brand name Dopergin among others, is a monoaminergic medication of the ergoline class which is used in the treatment of Parkinson's disease, migraine, and high prolactin levels. It is taken by mouth.

The orexin receptor (also referred to as the hypocretin receptor) is a G-protein-coupled receptor that binds the neuropeptide orexin. There are two variants, OX1 and OX2, each encoded by a different gene (HCRTR1, HCRTR2).

<span class="mw-page-title-main">Serotonin antagonist and reuptake inhibitor</span> Class of drug

Serotonin antagonist and reuptake inhibitors (SARIs) are a class of drugs used mainly as antidepressants, but also as anxiolytics and hypnotics. They act by antagonizing serotonin receptors such as 5-HT2A and inhibiting the reuptake of serotonin, norepinephrine, and/or dopamine. Additionally, most also antagonize α1-adrenergic receptors. The majority of the currently marketed SARIs belong to the phenylpiperazine class of compounds.

<span class="mw-page-title-main">Brexpiprazole</span> Atypical antipsychotic

Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.

A serotonin modulator and stimulator (SMS), sometimes referred to more simply as a serotonin modulator, is a type of drug with a multimodal action specific to the serotonin neurotransmitter system. To be precise, SMSs simultaneously modulate one or more serotonin receptors and inhibit the reuptake of serotonin. The term was created to describe the mechanism of action of the serotonergic antidepressant vortioxetine, which acts as a serotonin reuptake inhibitor (SRI), agonist of the 5-HT1A receptor, and antagonist of the 5-HT3 and 5-HT7 receptors. However, it can also technically be applied to vilazodone, which is an antidepressant as well and acts as an SRI and 5-HT1A receptor partial agonist.

<span class="mw-page-title-main">Amesergide</span> Chemical compound

Amesergide is a serotonin receptor antagonist of the ergoline and lysergamide families related to methysergide which was under development by Eli Lilly and Company for the treatment of a variety of conditions including depression, anxiety, schizophrenia, male sexual dysfunction, migraine, and thrombosis but was never marketed. It reached phase II clinical trials for the treatment of depression, erectile dysfunction, and premature ejaculation prior to the discontinuation of its development.

<span class="mw-page-title-main">Hypidone</span> Investigational antidepressant drug

Hypidone (developmental code name YL-0919) is an investigational serotonergic antidepressant which is under development for the treatment of major depressive disorder. It acts as a serotonin reuptake inhibitor, 5-HT1A receptor partial agonist, and 5-HT6 receptor full agonist. It is used as the hydrochloride salt. As of January 2021, hypidone is in phase 2 clinical trials for major depressive disorder.

Deuterated etifoxine is a deuterated drug which is under development for the treatment of anxiety disorders and mood disorders.

References

  1. ↑ "Riluzole sublingual - Biohaven Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  2. ↑ "TGFK 08AA - AdisInsight". adisinsight.springer.com.
  3. 1 2 "FKW 00GA - AdisInsight". adisinsight.springer.com.
  4. ↑ "Darigabat - Cerevel Therapeutics - AdisInsight". adisinsight.springer.com.
  5. 1 2 "JNJ 61393215 - AdisInsight". adisinsight.springer.com.
  6. ↑ "7-Oxoprasterone - Humanetics - AdisInsight". adisinsight.springer.com. Archived from the original on 2017-10-22.
  7. 1 2 Garakani A, Murrough JW, Iosifescu DV (2014). "Advances in Psychopharmacology for Anxiety Disorders". FOCUS. 12 (2): 152–162. doi: 10.1176/appi.focus.12.2.152 . ISSN   1541-4094.
  8. 1 2 Doggrell, S. A. (2007). Novel drugs and products in neuroscience. Drugs of the Future, 32(11), 1007-1017. https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3853&p_IsPs=Y
  9. 1 2 "BNC 210 - AdisInsight". adisinsight.springer.com.
  10. ↑ "Brexpiprazole - Lundbeck/Otsuka - AdisInsight". adisinsight.springer.com.
  11. ↑ "Iloperidone - Vanda Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  12. ↑ "Methylenedioxymetamfetamine - MAPS Europe B.V. - AdisInsight". adisinsight.springer.com.
  13. ↑ Sessa B (2017). "MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics"". Neurosci. Lett. 649: 176–180. doi:10.1016/j.neulet.2016.07.004. PMID   27394687. S2CID   3803704.
  14. ↑ Philipps D (29 November 2016). "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients". The New York Times. Retrieved 1 June 2017.
  15. ↑ "NBTX 001 - AdisInsight". adisinsight.springer.com.
  16. ↑ "Pomaglumetad methionil - Denovo Biopharma/Eli Lilly and Company - AdisInsight". adisinsight.springer.com.
  17. ↑ "Naloxone/tianeptine - Tonix Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  18. ↑ "Fasedienol - Pherin Pharmaceuticals/VistaGen Therapeutics - AdisInsight". adisinsight.springer.com.
  19. ↑ "JNJ 42165279 - AdisInsight". adisinsight.springer.com. Retrieved 2019-03-02.
  20. ↑ "A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder | Clinical Research Trial Listing ( Claustrophobia ) ( NCT02432703 )". www.centerwatch.com. Retrieved 2019-03-02.
  21. ↑ "Etifoxine deuterated - GABA Therapeutics - AdisInsight". adisinsight.springer.com.
  22. ↑ Rupprecht R, Pradhan AK, Kufner M, Brunner LM, Nothdurfter C, Wein S, Schwarzbach J, Puig X, Rupprecht C, Rammes G (December 2022). "Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options". Eur Arch Psychiatry Clin Neurosci. 273 (7): 1477–1487. doi:10.1007/s00406-022-01532-3. PMID   36574032. S2CID   255205221.
  23. ↑ "JNJ 42165279 - AdisInsight". adisinsight.springer.com.
  24. ↑ "AVN 101 - AdisInsight". adisinsight.springer.com.
  25. ↑ "Medipure Pharmaceutical MP-20X product line for anxiety". medipurepharmaceuticals. Archived from the original on 2016-10-29.
  26. ↑ "SRX 246 - AdisInsight". adisinsight.springer.com.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.